October 15, 2012Infectious Diseaseadmin Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved an update to the labeling for BARACLUDE® to include data on African Americans and liver transplant recipients with chronic hepatitis B infection.
